Pasithea Therapeutics (KTTAW) Competitors $0.02 0.00 (-11.57%) As of 06/20/2025 09:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock KTTAW vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CALAShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Calithera Biosciences 180 Life Sciences (NASDAQ:ATNFW) and Pasithea Therapeutics (NASDAQ:KTTAW) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, community ranking, dividends, media sentiment, valuation and earnings. Is ATNFW or KTTAW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Pasithea Therapeutics N/A N/A N/A Which has better earnings and valuation, ATNFW or KTTAW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/APasithea Therapeutics$486.56KN/AN/AN/AN/A Does the media prefer ATNFW or KTTAW? In the previous week, 180 Life Sciences had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for Pasithea Therapeutics. 180 Life Sciences' average media sentiment score of 0.95 beat Pasithea Therapeutics' score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Positive Pasithea Therapeutics Neutral Does the MarketBeat Community favor ATNFW or KTTAW? 180 Life Sciences and Pasithea Therapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/APasithea TherapeuticsN/AN/A Summary180 Life Sciences beats Pasithea Therapeutics on 2 of the 3 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTAW and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTAW vs. The Competition Export to ExcelMetricPasithea TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$121.39M$5.21B$8.54BDividend YieldN/A3.74%5.38%4.21%P/E RatioN/A3.2325.8019.17Price / SalesN/A4,196.13414.91109.16Price / CashN/A13.1935.3855.76Price / BookN/A44.527.925.76Net IncomeN/A-$92.79M$3.15B$248.88M7 Day PerformanceN/A0.79%1.27%2.13%1 Month PerformanceN/A3.91%4.64%3.77%1 Year PerformanceN/A183.47%41.92%15.59% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAWPasithea TherapeuticsN/A$0.02-11.6%N/A+12.4%$0.00$486.56K0.003Gap DownATNFW180 Life SciencesN/A$0.01+7.3%N/A-16.3%$0.00N/A0.007News CoveragePositive NewsLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.11+43.6%N/A+139.5%$0.00$106.21K0.0040Positive NewsALVOWAlvotechN/A$1.64flatN/A-51.0%$0.00$585.60M0.004Positive NewsGap DownACABWAtlantic Coastal Acquisition Corp. IIN/A$0.02+5.2%N/A-68.3%$0.00N/A0.0015Gap UpBFRIWBiofronteraN/A$0.09flatN/A+102.2%$0.00$38.00M0.0070Positive NewsGap DownBTMDWbioteN/A$0.03flatN/A-95.9%$0.00$199.38M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.07+0.9%N/A-79.8%$0.00N/A0.008News CoverageShort Interest ↑CALACalithera Biosciences0.5956 of 5 starsN/AN/AN/A$0.00N/A0.0060 Related Companies and Tools Related Companies 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives biote Alternatives BriaCell Therapeutics Alternatives Calithera Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KTTAW) was last updated on 6/22/2025 by MarketBeat.com Staff From Our PartnersWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KTTAW Stock Free KTTAW Stock Alerts